Related Experiment Video

Updated: Sep 18, 2025

Targeting Alpha Synuclein Aggregates in Cutaneous Peripheral Nerve Fibers by Free-floating Immunofluorescence Assay
08:33

Targeting Alpha Synuclein Aggregates in Cutaneous Peripheral Nerve Fibers by Free-floating Immunofluorescence Assay

Published on: June 25, 2019

8.4K

Renin-Angiotensin System Autoantibody Network in Parkinson's Disease Patients

Carmen M Labandeira1, Laura Camacho-Meño2, Paula Aracil-Pastor2

  • 1Neurology Service, University Hospital of Ourense, 32005 Ourense, Spain.

Antioxidants (Basel, Switzerland)
|June 26, 2025
PubMed

Insights

This study reveals a distinct network of autoantibodies targeting the renin-angiotensin system (RAS) in Parkinson's disease (PD). These findings highlight new potential biomarkers and therapeutic targets by linking immune and oxidative pathways in PD.

Area of Science:

  • Neuroimmunology
  • Cardiovascular Biology
  • Metabolic Pathways

Background:

  • The tissue renin-angiotensin system (RAS) regulates homeostasis via opposing axes.
  • Dysregulation of RAS contributes to diseases like Parkinson's disease (PD).
  • Elevated autoantibodies against AT1 and ACE2 are observed in PD, but other RAS components are unstudied.

Purpose of the Study:

  • To investigate autoantibodies against AT2 and MasR in PD.
  • To explore correlations among various RAS autoantibodies (RAS-AAs).
  • To examine links between RAS-AAs, cytokines, and 27-hydroxycholesterol in PD.

Main Methods:

  • Enzyme-linked immunosorbent assays (ELISAs) were used.
  • Serum samples from 106 controls and 117 PD patients were analyzed.
  • Correlations among RAS-AAs, cytokines, and 27-hydroxycholesterol were assessed.

Main Results:

  • PD patients showed increased MasR-AAs.
  • A more interconnected correlation network among RAS-AAs (AT1-AA, AT2-AA, MasR-AA, ACE2-AA) was observed in PD.
  • RAS-AA networks differed with sex and age, and linked to PD-related cytokines and 27-hydroxycholesterol.
  • AT1-AAs remained significantly associated with PD after adjustments.

Conclusions:

  • A disease-specific network of RAS autoantibodies exists in PD.
  • This network connects immune and oxidative pathways.
  • New biomarker patterns and potential therapeutic targets for PD are identified.
Keywords:
G protein-coupled receptorsParkinson’s diseaseaging-related changesangiotensin receptorsautoimmunitybiomarkerscytokinesneuroinflammationoxidative stresssex differences

More Related Videos

Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation12:49

Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation

Published on: March 21, 2020

7.6K
Anti-Nuclear Antibody Screening Using HEp-2 Cells13:01

Anti-Nuclear Antibody Screening Using HEp-2 Cells

Published on: June 23, 2014

135.4K

Related Concept Videos

Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
849
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
40.4K
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
90
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
911
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
949
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
524